Home Newsfeeds Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Needham Maintains Buy on PhaseBio Pharmaceuticals, Lowers Price Target to $8

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Needham analyst Serge Belanger maintains PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a Buy and lowers the price target from $10 to $8.

News

Kingswood Acquisition, Wentworth Management Services Announce Definitive Merger Agreement

By Benzinga Newsdesk

July 7, 4:02 PM

Kingswood Acquisition Corp. (NYSE:KWAC) ("KWAC"), announced today a definitive agreement to enter into a business combination with Wentworth Management Services LLC ("Wentworth"). The transaction

KWAC

Citigroup Maintains Neutral on Aramark, Raises Price Target to $45

By Benzinga Newsdesk

January 27, 12:55 PM

Citigroup analyst James Ainley maintains Aramark (NYSE:ARMK) with a Neutral and raises the price target from $39 to $45.

ARMK

Starbucks Joins McDonalds And Chipotle In Reporting A Remarkable Quarter Despite The Macroeconomic Challenges

By Upwallstreet

May 4, 1:02 PM

On Tuesday, Starbucks Corporation (NASDAQ: SBUX) topped both revenue and earnings estimates fueled by international sales. The coffee giant joined its fellow outliers, McDonald’s Corporation (NYSE: MCD) and Chipotle Mexican Grill

CMG